Eyeworld

Sumit "Sam" Garg, MD, is vice chair and medical director, Department of Ophthalmology, Gavin Herbert Eye Institute, University of Cali- fornia, Irvine, and a member of the ASCRS Young Eye Surgeons Clinical Committee. He can be contacted at gargs@uci.edu. Preeya Gupta, MD, is associ- ate professor of ophthal- mology, Duke University Eye Center, Durham, North Carolina. She can be contacted at preeya.gupta@duke.edu. Edward Holland, MD, is director of the Cornea Service, Cincinnati Eye Institute, and professor of ophthalmology, University of Cincinnati. He can be contacted at eholland@holprovision.com. Paul Karpecki, OD, is director of Corneal Services, Kentucky Eye Institute, Lexington, Kentucky, and at Gaddie Eye Centers, Louisville, Kentucky. He can be contacted at karpecki@karpecki.com. Terry Kim, MD, is profes- sor of ophthal- mology, chief of the Cornea and External Disease Division, and director of the Refractive Surgery Service, Duke University Eye Center, Durham, North Carolina. He can be contacted at terry.kim@ duke.edu. W. Barry Lee, MD, practices with Eye Consultants of Atlanta. He can be con- tacted at wblee@mac.com. Cynthia Matossian, MD, is med- ical director and founder, Matossian Eye Associates, Doylestown, Penn- sylvania and Hopewell, New Jersey. She can be contacted at cmatossian@matossianeye.com. Marguerite McDonald, MD, practices with Ophthal- mic Consultants of Long Island, is a clinical professor of ophthal- mology, New York University Langone Medical Center, New York, and a clinical professor of ophthalmology, Tulane Universi- ty Health Sciences Center, New Orleans. She can be contacted at margueritemcdmd@aol.com. Henry Perry, MD, practices with Ophthalmic Consultants of Long Island, Rockville Centre, New York, is director of the Corneal Service, Nassau University Medical Center, and medical director, Lions Eye Bank for Long Island, New York. He can be contacted at hankcornea@gmail.com. John Sheppard, MD, is pro- fessor of oph- thalmology, microbiology, and molecular biology, Eastern Virginia Medical School, med- ical director, Lions Eye Bank of Eastern Virginia, and president, Virginia Eye Consultants in Norfolk, Virginia. He can be contacted at docshep@hotmail. com. William Trattler, MD, is in practice at the Center for Excellence in Eye Care, Miami. He can be contacted at wtrattler@gmail.com. Elizabeth Yeu, MD, is assis- tant professor of ophthalmol- ogy, Eastern Virginia Medical School, and in private practice in Norfolk, Virginia. She can be contacted at eyeu@vec2020.com. Douglas Devries, OD, is co-founder, Eye Care Associates of Nevada, and adjunct clinical professor of optometry and residency director, Pacific University College of Optometry. He can be contacted at drdevries@ eyecareassociatesnv.com. Alice Epitropoulos, MD, is clinical assistant professor, The Ohio State University Wexner Med- ical Center, Columbus, Ohio, co-founder, the Eye Center of Columbus, and partner at Oph- thalmic Surgeons & Consultants of Ohio. She can be contacted at aepitrop@columbus.rr.com. Marjan Farid, MD, is director of cornea, cataract, and refractive surgery, vice chair of ophthalmic faculty, and professor of ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine. She can be contacted at mfarid@uci.edu. Meibomian gland dysfunction awareness grows M eibomian gland dysfunction (MGD) impacts quality of vi- sion and is the leading cause of dry eye, which can affect preop measurements and visual outcomes from cat- aract and refractive surgery. 1 Research continues to raise awareness of MGD. 2–4 Although 2015 ASCRS Clinical Survey respondents thought 37% of their dry eye patients had MGD, this num- ber increased to 55% by 2018. All 2019 Meibography Summit participants think the prevalence of MGD is increasing, which is attributed in part to aging, the average American diet, and increased use of electronic devices. A high percentage of cataract patients have MGD. "Most patients having cat- aract surgery are older, and they have never had therapy for their meibomian glands throughout their lifetime," said William Trattler, MD. Gupta et al. found that 80% of cataract patients had abnormal results for tear osmolarity, MMP-9, or both. 5 Cochener et al. reported that half of cataract surgery candidates with MGD had no symptoms and 56% had meibomian gland atrophy. 6 "After surgery, these patients usually become symptomatic. That is why it is very important to detect and pretreat patients to guarantee better results after surgery, especially patients receiving premium intraocular lenses (IOLs)," said Béatrice Co- chener-Lamard, MD, PhD. Users of digital devices blink less often, increasing the risk of MGD symptoms. "If you look at ocular surface in- terferometry, so many people have partial blinks," said W. Barry Lee, MD. While treating MGD, clinicians should educate patients about the importance The second Meibography Summit gathered top experts to discuss and define best practices for the diagnosis and treatment of meibomian gland dysfunction. Moderator Eric Donnenfeld, MD, practices with Ophthalmic Consultants of Long Island and Connecticut, and is a clinical professor of ophthal- mology, New York University, and trustee, Dartmouth Medical School. He can be contacted at ericdonnenfeld@gmail.com. Frank Bowden III, MD, is founder and president of Bowden Eye and Associ- ates, Jacksonville, Florida, as well as co-founder of the Dry Eye University Series. He can be contacted at fbowden3@ hotmail.com. Béatrice Cochener- Lamard, MD, PhD, is chair and professor of the ophthalmology department, Brest University Hospital, France, general secretary of EUCornea, and president of ESCRS. She can be contacted at beatrice.cochener-lamard@ chu-brest.fr. Faculty biographies continued on page 2 meibography summit: Better understanding of meibomian gland dysfunction and how to integrate meibography in diagnosis and treatment planning EyeWorld CME supplement

• Blank Page
• Blank Page (1)